HERA Call for tenders: €82 million for MCM development

We would like to make you aware of the recently published call for tenders that aims to speed up the development of innovative medical countermeasures with EUR 82million of HERA funding. The call has four lots targeting different MCMs:

  • Vaccines targeting bacterial infections caused by at least one of the twelve bacterial families classified as “priority pathogens” in the 2017 WHO Bacterial Priority Pathogens List or Mycobacterium tuberculosis (EUR 22 million)
  • Broad spectrum antivirals targeting respiratory diseases, mainly, but not limited to, Paramyxo-, Orthomyxo- and Coronaviridae (EUR 18 million)
  • Broad spectrum antivirals targeting viral-haemorrhagic fevers, mainly, but not limited to, Arena-, Bunya-, Flavi- and Filoviridae  (EUR 18 million)
  • Point of care metagenomic sequencing for universal pathogen detection (EUR 24 million)

The call supports clinical trials (from phase II) for medicinal products and development and certification for devices. All interested parties are invited to send in their applications by 4 December 2023, 16:00 (CET) on the eTendering portal, where all relevant documents can be found.

HaDEA and HERA are also holding an info session on the call on Monday, 23 October, 15.30 – 16.30, to which you can register here.